...
Mylan's generic version of
Bristol-Myers Squibb's Eliquis, meaning the drug cannot go to market until the
companies' patent suit is resolved. Eliquis, a leading blood thinner, currently
holds preferred status for 76% of covered lives.
SOURCE: MMIT Analytics, as of 7/16/19
No comments:
Post a Comment